MEDX logo

medmix AG Stock Price

SWX:MEDX Community·CHF 351.8m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author

MEDX Share Price Performance

CHF 8.65
-0.66 (-7.09%)
CHF 15.97
Fair Value
CHF 8.65
-0.66 (-7.09%)
45.8% undervalued intrinsic discount
CHF 15.97
Fair Value
Price CHF 8.65
AnalystConsensusTarget CHF 15.97
AnalystHighTarget CHF 20.00
AnalystLowTarget CHF 14.50

MEDX Community Narratives

AnalystConsensusTarget·
Fair Value CHF 15.97 45.8% undervalued intrinsic discount

Advanced Dental And Surgical Launches Will Expand Global Markets

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AnalystHighTarget·
Fair Value CHF 20 56.8% undervalued intrinsic discount

Long-Term Procedure Growth And Cost Efficiencies Will Transform Earnings Power

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystLowTarget·
Fair Value CHF 14.5 40.3% undervalued intrinsic discount

Tariff Risks And Execution Challenges Will Pressure Healthcare Devices Before Long-Term Trends Improve

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
CHF 20
56.8% undervalued intrinsic discount
Profit Margin
11.25%
Future PE
15.6x
Price in 2029
CHF 23.81
CHF 14.5
40.3% undervalued intrinsic discount
Profit Margin
5.56%
Future PE
24.51x
Price in 2028
CHF 17.33

Trending Discussion

Updated Narratives

MEDX logo

MEDX: Stable Dividend Outlook And Higher Required Return Will Support Upside

Fair Value: CHF 15.97 45.8% undervalued intrinsic discount
4 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
MEDX logo

Long-Term Procedure Growth And Cost Efficiencies Will Transform Earnings Power

Fair Value: CHF 20 56.8% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
MEDX logo

Tariff Risks And Execution Challenges Will Pressure Healthcare Devices Before Long-Term Trends Improve

Fair Value: CHF 14.5 40.3% undervalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Excellent balance sheet with moderate growth potential.

1 Risk
4 Rewards

medmix AG Key Details

CHF 448.0m

Revenue

CHF 286.1m

Cost of Revenue

CHF 161.9m

Gross Profit

CHF 155.5m

Other Expenses

CHF 6.4m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Jul 23, 2026
0.16
36.14%
1.43%
60.6%
View Full Analysis

About MEDX

Founded
1922
Employees
2574
CEO
Rene Willi
WebsiteView website
www.medmix.swiss

medmix AG designs, produces, and sells high-precision devices and services in Switzerland and internationally. It operates through the Healthcare, and Consumer and Industrial segments. The company offers dispensers, cartridges, mixers, tips, syringes, pen, and auto injectors for delivery of dental materials; delivery devices and mixing for bone repair and tissue treatment, which are used for prosthetics, restoratives, anesthetics, and aesthetics; the pen and auto injectors, which are used in fertility and growth hormone treatments, treatment of diabetes, osteoporosis, and other diseases; and the delivery and mixing devices, which are used by tissue banks and medical device OEMs. It also produces and markets dispensers, cartridges, and mixers for two-component adhesives and sealants for use in construction, transportation, electronics, infrastructure, and general industrial sectors; and micro-brushes and applicators for eyes, eyelashes, lips, and facial make-up. The company offers its products under the Mixpac, Transcodent, Qiaoyi, Cox, MK, Medmix, Haselmeier, and Geka brands. medmix AG was founded in 1922 and is based in Baar, Switzerland.

Recent MEDX News & Updates

Recent updates

No updates